This company listing is no longer active
CTI BioPharma Management
Management criteria checks 3/4
CTI BioPharma's CEO is Adam Craig, appointed in Mar 2017, they has a tenure of 6.25 years. Their total yearly compensation is $4.59M , comprised of 14.3% salary and 85.7% bonuses, including company stock and options. They directly owns 0.022% of the company’s shares, worth $267.56K. The average tenure of the management team and the board of directors is 6 years and 6.3 years respectively.
Key information
Adam Craig
Chief executive officer
US$4.6m
Total compensation
| CEO salary percentage | 14.3% |
| CEO tenure | 6.3yrs |
| CEO ownership | 0.02% |
| Management average tenure | 6yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch
Aug 17CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M
Aug 08CTI BioPharma: Approval Is Great, Now There's The Follow Through
Jul 19CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis
Jul 07CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset
May 04CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating
Apr 11CTI BioPharma: A Speculative Buy Into The PDUFA Date
Mar 01CTI BioPharma: Long And Troubled History, Finally Approaching Approval
Dec 24FDA grants 'priority review' status to CTI Biopharma's pacritinib NDA
Jun 01CTI BioPharma initiated buy at Stifel; cites potential in myelofibrosis
May 06CTI BioPharma: Accelerated Approval Pathway Looks Attractive
Dec 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$69m |
| Dec 31 2022 | US$5m | US$657k | -US$93m |
| Sep 30 2022 | n/a | n/a | -US$112m |
| Jun 30 2022 | n/a | n/a | -US$121m |
| Mar 31 2022 | n/a | n/a | -US$118m |
| Dec 31 2021 | US$2m | US$633k | -US$98m |
| Sep 30 2021 | n/a | n/a | -US$76m |
| Jun 30 2021 | n/a | n/a | -US$63m |
| Mar 31 2021 | n/a | n/a | -US$58m |
| Dec 31 2020 | US$3m | US$615k | -US$52m |
| Sep 30 2020 | n/a | n/a | -US$46m |
| Jun 30 2020 | n/a | n/a | -US$44m |
| Mar 31 2020 | n/a | n/a | -US$41m |
| Dec 31 2019 | US$2m | US$595k | -US$40m |
| Sep 30 2019 | n/a | n/a | -US$31m |
| Jun 30 2019 | n/a | n/a | -US$36m |
| Mar 31 2019 | n/a | n/a | -US$36m |
| Dec 31 2018 | US$3m | US$564k | -US$29m |
| Sep 30 2018 | n/a | n/a | -US$45m |
| Jun 30 2018 | n/a | n/a | -US$42m |
| Mar 31 2018 | n/a | n/a | -US$29m |
| Dec 31 2017 | US$6m | US$434k | -US$45m |
Compensation vs Market: Adam's total compensation ($USD4.59M) is about average for companies of similar size in the US market ($USD3.55M).
Compensation vs Earnings: Adam's compensation has increased whilst the company is unprofitable.
CEO
Adam Craig (57 yo)
6.3yrs
Tenure
US$4,592,646
Compensation
Dr. Adam R. Craig, M.D., Ph D., M.B.A., has been the Chief Executive Officer, President and Director of CTI BioPharma Corp. since March 20, 2017 and serves its Interim Chief Medical Officer. Dr. Craig serv...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.3yrs | US$4.59m | 0.022% $ 267.6k | |
| Executive VP | 5.8yrs | US$1.47m | 0.013% $ 155.7k | |
| Executive VP & Chief Commercial Officer | no data | US$597.30k | 0.0027% $ 32.4k | |
| Senior Director of Investor Relations | 15yrs | no data | no data | |
| Senior Vice President Global Pharmaceutical Operations | no data | no data | no data | |
| Executive VP & Chief of Staff | no data | no data | no data | |
| Senior Vice President of Biometrics | 4.6yrs | no data | no data |
6.0yrs
Average Tenure
65yo
Average Age
Experienced Management: CTIC's management team is seasoned and experienced (6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.3yrs | US$4.59m | 0.022% $ 267.6k | |
| Independent Director | 1.8yrs | US$301.12k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | 9.9yrs | no data | no data | |
| Independent Chairman of the Board | 5.9yrs | US$352.12k | 0% $ 0 | |
| Independent Director | 6yrs | US$317.62k | 0% $ 0 | |
| Independent Director | 7.4yrs | US$303.62k | 0.033% $ 392.1k | |
| Independent Director | 11.8yrs | US$319.12k | 0.037% $ 442.1k | |
| Independent Director | 6.4yrs | US$330.62k | 0% $ 0 |
6.3yrs
Average Tenure
65yo
Average Age
Experienced Board: CTIC's board of directors are considered experienced (6.3 years average tenure).